Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECODE: Haemodynamic Effects Of Semaglutide and Tirzepatide
NCT07483801Phase 4Not yet recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide, tirzepatide in hypertension (HTN), obesity, sponsored by Cambridge University Hospitals NHS Foundation Trust. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
03
Conditions
hypertension (HTN)obesity
Beyond the preview
Go deeper on NCT07483801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483801.